EMERGENT BIOSOLUTIONS INC. Impairment of Intangible Assets (Excluding Goodwill)
EMERGENT BIOSOLUTIONS INC. (EBS) reported Impairment of Intangible Assets (Excluding Goodwill) of $9.60 million for the 12-month period ending 2013-12-31, per its 10-K filed 2015-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2015-03-09
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2013-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2013-03-31 was $9.60M.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2012-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets (excluding goodwill) for fiscal 2013 was $9.60M, a 0.00% change from fiscal 2012.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets (excluding goodwill) for fiscal 2012 was $9.60M.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2013-12-31 | $9.60M 10-K · filed 2015-03-09 | |||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $9.60M 10-Q · filed 2013-08-06 | $9.60M derived: sum of 3 quarters · filed 2014-03-10 | |
| 2013-03-31 | $9.60M 10-Q · filed 2013-05-03 | $9.60M derived: sum of 2 quarters · filed 2014-03-10 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $9.60M 10-K · filed 2014-03-10 | ||
| 2012-09-30 | $9.60M 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |